Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

[Successful treatment of acute promyelocytic leukemia complicated by liver cirrhosis with all-trans retinoic acid and reduced-dose anthracycline chemotherapy].

Tytuł:
[Successful treatment of acute promyelocytic leukemia complicated by liver cirrhosis with all-trans retinoic acid and reduced-dose anthracycline chemotherapy].
Autorzy:
Taya Y; Department of Hematology, Toranomon Hospital.
Mitsuki T; Department of Hematology, Toranomon Hospital.
Kaji D; Department of Hematology, Toranomon Hospital.
Ishiwata K; Department of Hematology, Toranomon Hospital.
Wake A; Department of Hematology, Toranomon Hospital.
Źródło:
[Rinsho ketsueki] The Japanese journal of clinical hematology [Rinsho Ketsueki] 2018; Vol. 59 (12), pp. 2561-2566.
Typ publikacji:
Case Reports; Journal Article
Język:
Japanese
Imprint Name(s):
Publication: Tokyo : Japan Society Of Clinical Hematology
Original Publication: Tokyo, Rinsho Ketsueki Kondankai.
MeSH Terms:
Anthracyclines/*therapeutic use
Carcinoma, Hepatocellular/*therapy
Leukemia, Promyelocytic, Acute/*drug therapy
Liver Cirrhosis/*complications
Liver Neoplasms/*therapy
Tretinoin/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols ; Carcinoma, Hepatocellular/complications ; Chemoembolization, Therapeutic ; Humans ; Leukemia, Promyelocytic, Acute/complications ; Liver Neoplasms/complications ; Male ; Middle Aged ; Remission Induction
Contributed Indexing:
Keywords: Acute promyelocytic leukemia; All-trans retinoic acids; Liver cirrhosis
Substance Nomenclature:
0 (Anthracyclines)
5688UTC01R (Tretinoin)
Entry Date(s):
Date Created: 20190111 Date Completed: 20190702 Latest Revision: 20190702
Update Code:
20240104
DOI:
10.11406/rinketsu.59.2561
PMID:
30626789
Czasopismo naukowe
Although all-trans retinoic acids (ATRA) are most commonly used as agents in acute promyelocytic leukemia (APL), there are few reports on the administration of ATRAs to patients with liver insufficiency. We report two cases of APL; a 57-year-old man with APL complicated by liver cirrhosis (Child-Pugh class B) and hepatocellular carcinoma who is receiving transcatheter arterial chemoembolization (TACE) and a 50-year-old man with APL complicated by liver cirrhosis (Child-Pugh class B) who is being prepared for receiving a living-donor liver transplantation. Both patients were successfully treated with a normal dosage of ATRA alone during remission-induction therapy. Because the total bilirubin and hepatic transaminases in the two cases were almost at normal levels; the patients received three courses of ATRAs plus a 42%-70% dose of anthracyclines as a consolidation therapy. At 1 year after receiving intermittent ATRA therapy, the patients are maintaining molecular remission. These cases suggest that the administration of ATRA and modifications of doses of chemotherapeutic agents are applicable to APL patients with liver dysfunction.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies